A small clinical test consisting of 12 patients has yielded a 100% success against rectal cancer. This test was held by doctors at the Memorial Sloan Kettering Cancer Center in New York. The test was used to run a trial on the drug Dostarlimab on individuals with locally advanced rectal cancer, meaning that the cancer spread within the rectum but did not make its way to other organs. All patients saw the complete disappearance of cancerous growth and tissue.
According to a research article published by the doctors that took part in the study, the patients were given Dostarlimab every three weeks for six months and were then going to undergo chemotherapy or surgery. However, the use of Dostarlimab was so effective that patients did not have to undergo any further procedures after taking the six-month cycle of the medication.
The same article has stated that the patients did not suffer from any adverse effects after their treatment cycle with Dostarlimab and after none of the patients have experienced any recurrence in rectal cancer during at least six months of follow-up.
According to drugs.com, a site that provides informational materials on drugs and medications that may be given to patients, Dostarlimab is an anti-PD-1 monoclonal antibody. Once taken, the drug will enable tumorous growths to be recognized by the body and thus destroyed. However, a single dose of Dostarlimab can cost a little over $11,000.
Cancer is one of the diseases that unites us through the grief that it inflicts on us all, whether directly or indirectly. Although this test has only seen results for rectal cancer, this is an incredible step towards more broad victories against the disease in the future.
